Medifast (MED) Wobbles on Slower Start: Fewer Active Coaches, Still-Looming Questions in Q1 2026

Ticker: MED • EPS: -$0.19 (diluted) • Revenue: $76.0 million • Reported May 2026

Lead: a quarter of transformation with a price tag

Medifast, the metabolic health and wellness company trading as MED on the NYSE, reported its first quarter 2026 results for the period ended March 31, 2026. Revenue fell to $76.0 million, down 34.3% from $115.7 million a year earlier. The company booked a net loss of $2.1 million, or $0.19 per diluted share, while cash, cash equivalents and investment securities totaled $168.9 million with no debt. The headline data are blunt: fewer active earning coaches, lower revenue per coach, and an operating loss, even as management touts discipline and a path back to growth. The tone is not celebratory, but it isn’t a total eulogy either—more of a pivot with a cost anchor.

Key numbers at a glance

Revenue: $76.0 million; down 34.3% year over year, from $115.7 million in Q1 2025.
Active earning coaches: 14,000, down 44.9% from 25,400 a year ago.
Revenue per active earning coach: $5,432, up 19.2% from $4,556.
Net loss: $2.1 million, or EPS of $0.19 per diluted share.
Gross profit: $51.8 million; gross margin 68.1% vs 72.8% a year earlier.
SG&A: $55.1 million, or 72.4% of revenue, down from 73.9% in Q1 2025.
Loss from operations: $3.3 million; 4.3% of revenue, vs 1.1% in the prior-year period.
Balance sheet: $168.9 million in cash and investments; no debt.
One-time impact: $2.2 million gain on sale of the Maryland Distribution Center; offsetting driver of SG&A decline.

Narrative and nuance: what the numbers imply

The topline drop is explained, in the company's words, by a contraction in the roster of active earning coaches—an effect that compounds the revenue weakness as the company pivots toward its metabolic health strategy. The rise in revenue per coach is a nod toward better-than-raw leverage within a leaner network, but you don’t get to a positive P&L on a single metric improving while the overall coach base shrinks. In other words, the math on the left side of the ledger is still fighting the math on the right.

The earnings per diluted share (EPS) line sits in negative territory at -$0.19, a reminder that even with a one-time gain on the Maryland asset, the underlying business is not yet profitable on a quarterly basis. The company underscores that the SG&A decline was driven by lower coach compensation tied to volume, less marketing spend, and a one-time gain from the asset sale. Those deflationary tailwinds are meaningful, but they aren’t a substitute for a sustained recovery in revenue and in the coached-network ecosystem.

Cost structure, leverage, and the lingering question of growth

A few structural observations stand out. First, gross margin declined to 68.1% from 72.8%, with the company signaling that lower sales volume has reduced fixed-cost leverage. In other words, as volume contracts, the company loses some of the cushion that a mature cost base would typically enjoy. Second, SG&A as a percentage of revenue declined by about 150 basis points year over year, but the narrative attributes much of that to a mix of lower coach compensation and one-time gains rather than a sustained reengineering of the cost base.

The higher-level strategic question is whether the company’s “coaching network” can reaccelerate. The press release emphasizes progress in coach productivity, leadership, and field engagement as leading indicators of future growth. The persistence of a shrinking coach base, amid broader weight-management dynamics and the rapid adoption of GLP-1 medications, raises questions about the pace and source of any near-term revenue recovery.

Outlook and sector implications: what peers might watch

Management does not provide a formal revenue forecast in this release, signaling caution about near-term visibility. The absence of explicit guidance can be a signal for investors to price in more volatility as the company navigates its transformation. From a sector perspective, Medifast’s experience sits at the intersection of consumer wellness, weight-management technology, and the friction of a shifting regulatory and consumer landscape around weight-loss therapies.

For peers, the story may portend a renewed emphasis on unit economics—coaching efficiency, conversion of coaching activity into durable revenue, and the balance between marketing spend and coach compensation. If GLP-1 adoption continues to affect traditional weight-management channels, companies with agile cost structures and adaptable coach networks could outperform on a relative basis, even if absolute revenue remains under pressure.

Bottom line: discipline today, potential tomorrow

Medifast is signaling discipline—cost control, portfolio realignment, and a focus on a scientifically grounded, coach-led system. The Q1 numbers show a company in transition rather than collapsed resilience, with a negative EPS near-term outcome but a balance sheet that offers a cushion to weather the storm while pursuing the strategic pivot.

For investors tracking the EPS trajectory, the upcoming quarters will hinge on whether the coach network stabilizes, whether revenue per coach continues to improve, and whether the company can translate a leaner cost structure into sustainable profitability. The presence of a one-time gain muddies the apples-to-apples comparison, so operators will watch for earnings surprises that are anchored in recurring performance.

In the near term, the market will likely weigh: EPS data against the trend in active coaches, the pathway back to revenue forecast clarity, and the durability of gross margins as the company navigates its transformation—an exercise every sector peer will be reading as a case study in the cost of pivoting from growth to sustainability.